Memantine
Cancer Or Benign Tumor
NRG OncologySmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Cancer Or Benign Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Emory University | Phase 1 | CCC |
Larotrectinib Children's Oncology Group | Phase 2 | CCC |
Cabozantinib National Cancer Institute (NCI) | Phase 2 | CCC |
Carboplatin Emory University | Phase 1 | CCC |
Veliparib National Cancer Institute (NCI) | Phase 1 | CCC |
View all 24 →
Same molecule, other indications
Memantine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →